Current Articles | Archived Articles
Articles From The Most Current Issue of OBR
ON-CURRENCES
Sat, Nov 01, 2008
Tracking the movement of oncology business personnel and other news-making events in the oncology community.[ read article ]
ON-CONVERSATIONS: HillCo Partners Identifies Major Healthcare Policy Trends Which Will Impact Oncology Over the Next 3 to 5 Years
Sat, Nov 01, 2008
HillCo Partners Identifies Major Healthcare Policy Trends Which Will Impact Oncology Over the Next 3 to 5 Years[ read article ]
Planning to Maximize the Economics of Clinical Trials
Sat, Nov 01, 2008
With economics in mind, practices must adequately plan, forecast, implement, and manage their clinical trials program in order to avoid costly pitfalls.[ read article ]
Oncology Clinical Trials: The New Battleground?
Sat, Nov 01, 2008
In a survey of 50 oncologists conducted by Market Strategies International, we gain insights into the hurdles to clinical trial accrual, where oncologists learn about studies, and which companies they have had positive clinical trial experience with[ read article ]
Productive Partnering—The Next Stage in Patient Enrollment for Clinical Trials
Sat, Nov 01, 2008
Patients, oncologists, and the industry as a whole benefit from having the broadest possible range of effective treatment options. The availability of these treatments depends upon successful patient recruitment to clinical trials. Patient advocates, community oncologists, and study sponsors each play a critical role in increasing patient recruitment.[ read article ]
Creating Comparative Effectiveness Policy: How Does Oncology Fit?
Sat, Nov 01, 2008
To date, comparative effectiveness (CE) hasn’t been focused on oncology, but this could change given the current environment. Comparative effectiveness isn’t just about “choosing the cheaper drug” and most agree that using CE studies to find a lower cost alternative would likely waste financial resources. So where does oncology fit in with CE? What about private payers? What do they want from industry? We explore CE’s impact on oncology from multiple perspectives.[ read article ]
Prospecting In Oncology: Analytical Framework Guides Development Strategy Decisions
Sat, Nov 01, 2008
In a crowded market like the oncology industry, early-stage development decisions have long-term implications. A good analytical process, proposed here by IMS, takes into account internal and external factors and must be implemented early on to prevent failures and maximize returns.[ read article ]
Oncology Compendia: Greater Transparency and Regulatory Attention at the Forefront
Sat, Nov 01, 2008
As we enter an era of accountability and financial scrutiny, CMS is set to take a lead role with federal and state agencies to ensure compendia remain a vital resource for off-label treatment decisions—but that they become free of conflict.[ read article ]